ArticleImmunoTargets and therapy2026
Enhancing NK Cell Activity in Colorectal Cancer with an Fc-Optimized Antibody Targeting CD276 (B7-H3).
Article in ImmunoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Colorectal cancer (CRC) represents a major global health burden due to its high incidence and mortality, particularly in the advanced stages, with limited treatment options. While therapies that block the PD-1/PD-L1 pathway have demonstrated clinical benefit, their success in CRC is largely confined to patients with high microsatellite instability (MSI-H) tumors. Innovative immunotherapeutic solutions are critically needed for the majority of CRC cases. CD276 (B7-H3), a B7 family immune checkpoint molecule, is overexpressed in many cancers including CRC. Significant CD276 upregulation in CRC cell lines compared to benign tissues has been previously demonstrated. In this study, the potential of an Fc-optimized anti-CD276 monoclonal antibody to enhance natural killer (NK) cell activity in CRC was evaluated. Methods: An Fc-optimized monoclonal antibody, 8H8_SDIE, was developed to enhance NK cell activity by increasing CD16 binding. In vitro experiments were conducted using human CRC cell lines and peripheral blood mononuclear cells (PBMCs) from healthy adult donors to evaluate the binding specificity of 8H8_SDIE to CD276. NK cell activation was assessed by measuring the upregulation of activation markers (CD69, CD25, and CD107a) and secretion of cytotoxic mediators (IFNγ, granzyme B, and perforin). Cytotoxicity assays were performed to determine NK cell-mediated tumor cell lysis. Results: 8H8_SDIE specifically bound to CD276-positive CRC cells and significantly enhanced NK cell activation. These effects included increased levels of activation and cytotoxic mediators. In cytotoxicity assays, 8H8_SDIE demonstrated potent NK cell-mediated lysis of CRC cells. Conclusion: The Fc-optimized anti-CD276 antibody 8H8_SDIE effectively enhanced NK cell reactivity against CD276-positive CRC cells and induced tumor cell lysis in vitro. These findings suggest that 8H8_SDIE holds potential as a novel immunotherapeutic candidate for CRC, particularly for patients with microsatellite-stable disease, and warrants further evaluation in advanced preclinical and future clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.